Numeric Investors LLC Buys New Position in Portola Pharmaceuticals, Inc. (PTLA)

Numeric Investors LLC bought a new position in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,400 shares of the biopharmaceutical company’s stock, valued at approximately $753,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Portola Pharmaceuticals by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,614,814 shares of the biopharmaceutical company’s stock worth $180,855,000 after acquiring an additional 192,420 shares during the last quarter. BlackRock Inc. raised its stake in shares of Portola Pharmaceuticals by 0.9% in the second quarter. BlackRock Inc. now owns 4,071,966 shares of the biopharmaceutical company’s stock worth $228,721,000 after acquiring an additional 37,241 shares during the last quarter. FMR LLC raised its stake in shares of Portola Pharmaceuticals by 5.6% in the first quarter. FMR LLC now owns 3,902,000 shares of the biopharmaceutical company’s stock worth $152,919,000 after acquiring an additional 205,751 shares during the last quarter. Northern Trust Corp raised its stake in shares of Portola Pharmaceuticals by 3.2% in the second quarter. Northern Trust Corp now owns 635,998 shares of the biopharmaceutical company’s stock worth $35,724,000 after acquiring an additional 19,719 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS bought a new position in shares of Portola Pharmaceuticals in the second quarter worth about $29,483,000. 85.02% of the stock is owned by institutional investors.

Shares of Portola Pharmaceuticals, Inc. (PTLA) opened at 53.29 on Friday. The stock’s 50 day moving average is $55.94 and its 200 day moving average is $49.33. Portola Pharmaceuticals, Inc. has a 12 month low of $15.68 and a 12 month high of $67.10. The firm’s market cap is $3.07 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.12). The business had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.28 million. Portola Pharmaceuticals had a negative net margin of 807.93% and a negative return on equity of 145.12%. The firm’s quarterly revenue was down 10.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.02) EPS. Analysts forecast that Portola Pharmaceuticals, Inc. will post ($4.82) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Numeric Investors LLC Buys New Position in Portola Pharmaceuticals, Inc. (PTLA)” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2957166/numeric-investors-llc-buys-new-position-in-portola-pharmaceuticals-inc-ptla.html.

PTLA has been the subject of a number of research analyst reports. BidaskClub raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Zacks Investment Research raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $70.00 target price for the company in a research note on Tuesday, July 18th. Citigroup Inc. boosted their target price on shares of Portola Pharmaceuticals from $51.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday, June 26th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a research note on Wednesday, September 6th. Finally, Credit Suisse Group set a $70.00 target price on shares of Portola Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, August 10th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $65.15.

In related news, EVP Tao Fu sold 5,812 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total value of $377,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John T. Curnutte sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total transaction of $650,000.00. The disclosure for this sale can be found here. 4.90% of the stock is owned by company insiders.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.